Cellular senescence as a possible link between prostate diseases of the ageing male.
Aging
/ immunology
Cellular Microenvironment
/ immunology
Cellular Senescence
/ immunology
Cytokines
/ immunology
Humans
Inflammation
/ immunology
Male
Prostate
/ cytology
Prostatic Diseases
/ immunology
Prostatic Hyperplasia
/ immunology
Prostatic Neoplasms
/ immunology
Senescence-Associated Secretory Phenotype
/ immunology
Tumor Microenvironment
/ immunology
Journal
Nature reviews. Urology
ISSN: 1759-4820
Titre abrégé: Nat Rev Urol
Pays: England
ID NLM: 101500082
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
accepted:
15
06
2021
pubmed:
24
7
2021
medline:
29
1
2022
entrez:
23
7
2021
Statut:
ppublish
Résumé
Senescent cells accumulate with age in all tissues. Although senescent cells undergo cell-cycle arrest, these cells remain metabolically active and their secretome - known as the senescence-associated secretory phenotype - is responsible for a systemic pro-inflammatory state, which contributes to an inflammatory microenvironment. Senescent cells can be found in the ageing prostate and the senescence-associated secretory phenotype and can be linked to BPH and prostate cancer. Indeed, a number of signalling pathways provide biological plausibility for the role of senescence in both BPH and prostate cancer, although proving causality is difficult. The theory of senescence as a mechanism for prostate disease has a number of clinical implications and could offer opportunities for targeting in the future.
Identifiants
pubmed: 34294916
doi: 10.1038/s41585-021-00496-8
pii: 10.1038/s41585-021-00496-8
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
597-610Subventions
Organisme : Medical Research Council
ID : MR/P00184X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S005897/1
Pays : United Kingdom
Informations de copyright
© 2021. Springer Nature Limited.
Références
Berry, S. J., Coffey, D. S., Walsh, P. C. & Ewing, L. L. The development of human benign prostatic hyperplasia with age. J. Urol. 132, 474–479 (1984).
pubmed: 6206240
doi: 10.1016/S0022-5347(17)49698-4
Soos, G. et al. The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study. Eur. Urol. 48, 739–744 (2005).
pubmed: 16203079
doi: 10.1016/j.eururo.2005.08.010
Bell, K. J. L., Del Mar, C., Wright, G., Dickinson, J. & Glasziou, P. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int. J. Cancer 137, 1749–1757 (2015).
pubmed: 25821151
pmcid: 4682465
doi: 10.1002/ijc.29538
McNeal, J. E. The zonal anatomy of the prostate. Prostate 2, 35–49 (1981).
pubmed: 7279811
doi: 10.1002/pros.2990020105
McNeal, J. E., Redwine, E. A., Freiha, F. S. & Stamey, T. A. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am. J. Surg. Pathol. 12, 897–906 (1988).
pubmed: 3202246
doi: 10.1097/00000478-198812000-00001
Turkbey, B. et al. Age-related changes in prostate zonal volumes as measured by high-resolution magnetic resonance imaging (MRI): a cross-sectional study in over 500 patients. BJU Int. 110, 1642–1647 (2012).
pubmed: 22973825
doi: 10.1111/j.1464-410X.2012.11469.x
De Nunzio, C. et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur. Urol. 60, 106–117 (2011).
pubmed: 21497433
doi: 10.1016/j.eururo.2011.03.055
Cai, T. et al. Current knowledge of the potential links between inflammation and prostate cancer. Int. J. Mol. Sci. 20, 3833 (2019).
pmcid: 6696519
doi: 10.3390/ijms20153833
van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014).
pubmed: 24848057
pmcid: 4214092
doi: 10.1038/nature13193
Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585–621 (1961).
pubmed: 13905658
doi: 10.1016/0014-4827(61)90192-6
Coppé, J.-P., Desprez, P.-Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99–118 (2010).
pubmed: 20078217
pmcid: 4166495
doi: 10.1146/annurev-pathol-121808-102144
Campisi, J. & d’Adda di Fagagna, F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8, 729–740 (2007).
pubmed: 17667954
doi: 10.1038/nrm2233
Franceschi, C. & Campisi, J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J. Gerontol. A. Biol. Sci. Med. Sci. 69 (Suppl. 1), S4–S9 (2014).
pubmed: 24833586
doi: 10.1093/gerona/glu057
Huda, N. et al. Hepatic senescence, the good and the bad. World J. Gastroenterol. 25, 5069–5081 (2019).
pubmed: 31558857
pmcid: 6747293
doi: 10.3748/wjg.v25.i34.5069
Xu, M. et al. Transplanted senescent cells induce an osteoarthritis-like condition in mice. J. Gerontol. A. Biol. Sci. Med. Sci. 72, 780–785 (2017).
pubmed: 27516624
doi: 10.1093/gerona/glw186
Baker, D. J. et al. Clearance of p16
pubmed: 22048312
pmcid: 3468323
doi: 10.1038/nature10600
Xu, M. et al. Senolytics improve physical function and increase lifespan in old age. Nat. Med. 24, 1246–1256 (2018).
pubmed: 29988130
pmcid: 6082705
doi: 10.1038/s41591-018-0092-9
Roos, C. M. et al. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell 15, 973–977 (2016).
pubmed: 26864908
pmcid: 5013022
doi: 10.1111/acel.12458
Yousefzadeh, M. J. et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36, 18–28 (2018).
pubmed: 30279143
pmcid: 6197652
doi: 10.1016/j.ebiom.2018.09.015
Adamus, J., Aho, S., Meldrum, H., Bosko, C. & Lee, J.-M. p16INK4A influences the aging phenotype in the living skin equivalent. J. Invest. Dermatol. 134, 1131–1133 (2014).
pubmed: 24335897
doi: 10.1038/jid.2013.468
Waaijer, M. E. C. et al. The number of p16INK4a positive cells in human skin reflects biological age. Aging Cell 11, 722–725 (2012).
pubmed: 22612594
doi: 10.1111/j.1474-9726.2012.00837.x
Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363–9367 (1995).
pubmed: 7568133
pmcid: 40985
doi: 10.1073/pnas.92.20.9363
Smith, J. R. & Pereira-Smith, O. M. Replicative senescence: implications for in vivo aging and tumor suppression. Science 273, 63–67 (1996).
pubmed: 8658197
doi: 10.1126/science.273.5271.63
Byun, H.-O. et al. Cathepsin D and eukaryotic translation elongation factor 1 as promising markers of cellular senescence. Cancer Res. 69, 4638–4647 (2009).
pubmed: 19487283
doi: 10.1158/0008-5472.CAN-08-4042
Pruitt, F. L. et al. Cathepsin D acts as an essential mediator to promote malignancy of benign prostatic epithelium. Prostate 73, 476–488 (2013).
pubmed: 22996917
doi: 10.1002/pros.22589
Kuilman, T., Michaloglou, C., Mooi, W. J. & Peeper, D. S. The essence of senescence. Genes Dev. 24, 2463–2479 (2010).
pubmed: 21078816
pmcid: 2975923
doi: 10.1101/gad.1971610
Biran, A. et al. Quantitative identification of senescent cells in aging and disease. Aging Cell 16, 661–671 (2017).
pubmed: 28455874
pmcid: 5506427
doi: 10.1111/acel.12592
Childs, B. G., Bussian, T. J. & Baker, D. J. Cellular Identification and quantification of senescence-associated β-galactosidase activity in vivo. Methods Mol. Biol. 1896, 31–38 (2019).
pubmed: 30474837
pmcid: 6410569
doi: 10.1007/978-1-4939-8931-7_4
Pereira, B. I. et al. Senescent cells evade immune clearance via HLA-E-mediated NK and CD8
pubmed: 31160572
pmcid: 6547655
doi: 10.1038/s41467-019-10335-5
Schwarze, S. R., Fu, V. X., Desotelle, J. A., Kenowski, M. L. & Jarrard, D. F. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia 7, 816–823 (2005).
pubmed: 16229804
pmcid: 1501939
doi: 10.1593/neo.05250
Halvorsen, O. J., Haukaas, S., Høisæter, P. Å. & Akslen, L. A. Expression of p 16 protein in prostatic adenocarcinomas, intraepithelial neoplasia, and benign/hyperplastic glands. Urol. Oncol. 3, 59–66 (1997).
pubmed: 21227061
doi: 10.1016/S1078-1439(97)00038-0
Zhang, Z., Rosen, D. G., Yao, J. L., Huang, J. & Liu, J. Expression of p14
pubmed: 16799475
doi: 10.1038/modpathol.3800655
Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725–730 (2005).
pubmed: 16079851
pmcid: 1939938
doi: 10.1038/nature03918
Alimonti, A. et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J. Clin. Invest. 120, 681–693 (2010).
pubmed: 20197621
pmcid: 2827955
doi: 10.1172/JCI40535
Pernicová, Z. et al. Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2. Neoplasia 13, 526–536 (2011).
pubmed: 21677876
pmcid: 3114246
doi: 10.1593/neo.11182
Ewald, J. A. et al. Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo. Prostate 73, 337–345 (2013).
pubmed: 22911222
doi: 10.1002/pros.22571
Parisotto, M. et al. PTEN deletion in luminal cells of mature prostate induces replication stress and senescence in vivo. J. Exp. Med. 215, 1749–1763 (2018).
pubmed: 29743291
pmcid: 5987915
doi: 10.1084/jem.20171207
Hensley, P. J. & Kyprianou, N. Modeling prostate cancer in mice: limitations and opportunities. J. Androl. 33, 133–144 (2012).
pubmed: 21680808
doi: 10.2164/jandrol.111.013987
Collado, M. & Serrano, M. Senescence in tumours: evidence from mice and humans. Nat. Rev. Cancer 10, 51–57 (2010).
pubmed: 20029423
pmcid: 3672965
doi: 10.1038/nrc2772
Oliveira, D. S. M. et al. The mouse prostate: a basic anatomical and histological guideline. Bosn. J. Basic. Med. Sci. 16, 8–13 (2016).
pubmed: 26773172
pmcid: 4765945
Choi, J. et al. Expression of senescence-associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia. Urology 56, 160–166 (2000).
pubmed: 10869659
doi: 10.1016/S0090-4295(00)00538-0
Castro, P., Giri, D., Lamb, D. & Ittmann, M. Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate 55, 30–38 (2003).
pubmed: 12640658
doi: 10.1002/pros.10204
Vital, P., Castro, P., Tsang, S. & Ittmann, M. The senescence-associated secretory phenotype promotes benign prostatic hyperplasia. Am. J. Pathol. 184, 721–731 (2014).
pubmed: 24434012
pmcid: 3936307
doi: 10.1016/j.ajpath.2013.11.015
Jiang, S., Song, C. S. & Chatterjee, B. Stimulation of prostate cells by the senescence phenotype of epithelial and stromal cells: implication for benign prostate hyperpalsia. FASEB BioAdvances 1, 353–363 (2019).
pubmed: 31844843
pmcid: 6914307
Shapiro, E., Becich, M. J., Hartanto, V. & Lepor, H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J. Urol. 147, 1293–1297 (1992).
pubmed: 1373778
doi: 10.1016/S0022-5347(17)37546-8
Vernier, M. et al. Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev. 25, 41–50 (2011).
pubmed: 21205865
pmcid: 3012935
doi: 10.1101/gad.1975111
Deschênes-Simard, X. et al. Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev. 27, 900–915 (2013).
pubmed: 23599344
pmcid: 3650227
doi: 10.1101/gad.203984.112
Krtolica, A. & Campisi, J. Integrating epithelial cancer, aging stroma and cellular senescence. Adv. Gerontol. 11, 109–116 (2003).
pubmed: 12820530
McNeal, J. E. Origin and evolution of benign prostatic enlargement. Invest. Urol. 15, 340–345 (1978).
pubmed: 75197
Untergasser, G., Madersbacher, S. & Berger, P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp. Gerontol. 40, 121–128 (2005).
pubmed: 15763388
doi: 10.1016/j.exger.2004.12.008
Bierhoff, E. et al. Morphological analogies of fetal prostate stroma and stromal nodules in BPH. Prostate 31, 234–240 (1997).
pubmed: 9180933
doi: 10.1002/(SICI)1097-0045(19970601)31:4<234::AID-PROS4>3.0.CO;2-K
Cunha, G. R. & Ricke, W. A. A historical perspective on the role of stroma in the pathogenesis of benign prostatic hyperplasia. Differ. Res. Biol. Divers. 82, 168–172 (2011).
doi: 10.1016/j.diff.2011.04.002
Muñoz-Espín, D. et al. Programmed cell senescence during mammalian embryonic development. Cell 155, 1104–1118 (2013).
pubmed: 24238962
doi: 10.1016/j.cell.2013.10.019
Felka, T. et al. Loss of spatial organization and destruction of the pericellular matrix in early osteoarthritis in vivo and in a novel in vitro methodology. Osteoarthritis Cartilage 24, 1200–1209 (2016).
pubmed: 26879798
pmcid: 4907798
doi: 10.1016/j.joca.2016.02.001
Price, J. S. et al. The role of chondrocyte senescence in osteoarthritis. Aging Cell 1, 57–65 (2002).
pubmed: 12882354
doi: 10.1046/j.1474-9728.2002.00008.x
Childs, B. G. et al. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science 354, 472–477 (2016).
pubmed: 27789842
pmcid: 5112585
doi: 10.1126/science.aaf6659
Harman, S. M. et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J. Clin. Endocrinol. Metab. 86, 724–731 (2001).
pubmed: 11158037
doi: 10.1210/jcem.86.2.7219
Roehrborn, C. G., Marks, L. & Harkaway, R. Enlarged prostate: a landmark national survey of its prevalence and impact on US men and their partners. Prostate Cancer Prostatic Dis. 9, 30–34 (2006).
pubmed: 16231014
doi: 10.1038/sj.pcan.4500841
Thompson, I. M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215–224 (2003).
pubmed: 12824459
doi: 10.1056/NEJMoa030660
Kristal, A. R. et al. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am. J. Epidemiol. 168, 1416–1424 (2008).
pubmed: 18945688
pmcid: 2727187
doi: 10.1093/aje/kwn272
Boyle, P. et al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int. 118, 731–741 (2016).
pubmed: 26779889
doi: 10.1111/bju.13417
Mohamad, N.-V. et al. The relationship between circulating testosterone and inflammatory cytokines in men. Aging Male 22, 129–140 (2019).
pubmed: 29925283
doi: 10.1080/13685538.2018.1482487
Chen, Y.-Q. et al. Testosterone ameliorates vascular aging via the Gas6/Axl signaling pathway. Aging 12, 16111–16125 (2020).
pubmed: 32717722
pmcid: 7485733
doi: 10.18632/aging.103584
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
De Nunzio, C., Presicce, F. & Tubaro, A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat. Rev. Urol. 13, 613–626 (2016).
pubmed: 27686153
doi: 10.1038/nrurol.2016.168
Nickel, J. C. et al. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int. 87, 797–805 (2001).
pubmed: 11412216
doi: 10.1046/j.1464-410x.2001.02193.x
Nickel, J. C. Prostatitis. Can. Urol. Assoc. J. 5, 306–315 (2011).
pubmed: 22031609
pmcid: 3202001
doi: 10.5489/cuaj.686
Sfanos, K. S., Yegnasubramanian, S., Nelson, W. G. & De Marzo, A. M. The inflammatory microenvironment and microbiome in prostate cancer development. Nat. Rev. Urol. 15, 11–24 (2018).
pubmed: 29089606
doi: 10.1038/nrurol.2017.167
Robert, G. et al. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 69, 1774–1780 (2009).
pubmed: 19670242
pmcid: 2833181
doi: 10.1002/pros.21027
Delongchamps, N. B. et al. Evaluation of prostatitis in autopsied prostates — is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J. Urol. 179, 1736–1740 (2008).
pubmed: 18343414
pmcid: 2661538
doi: 10.1016/j.juro.2008.01.034
McConnell, J. D. et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 349, 2387–2398 (2003).
pubmed: 14681504
doi: 10.1056/NEJMoa030656
Torkko, K. C. et al. Prostate biopsy markers of inflammation are associated with risk of clinical progression of benign prostatic hyperplasia: findings from the MTOPS study. J. Urol. 194, 454–461 (2015).
pubmed: 25828974
doi: 10.1016/j.juro.2015.03.103
Vesalainen, S., Lipponen, P., Talja, M. & Syrjänen, K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur. J. Cancer 30, 1797–1803 (1994).
doi: 10.1016/0959-8049(94)E0159-2
Irani, J. et al. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Urology 54, 467–472 (1999).
pubmed: 10475356
doi: 10.1016/S0090-4295(99)00152-1
Rani, A., Dasgupta, P. & Murphy, J. J. Prostate cancer: the role of inflammation and chemokines. Am. J. Pathol. 189, 2119–2137 (2019).
pubmed: 31421072
doi: 10.1016/j.ajpath.2019.07.007
Sfanos, K. S., Yegnasubramanian, S., Nelson, W. G. & De Marzo, A. M. The inflammatory microenvironment and microbiome in prostate cancer development. Nat. Rev. Urol. 15, 11–24 (2017).
pubmed: 29089606
doi: 10.1038/nrurol.2017.167
De Marzo, A. M. et al. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 7, 256–269 (2007).
pubmed: 17384581
pmcid: 3552388
doi: 10.1038/nrc2090
De Marzo, A. M., Haffner, M. C., Lotan, T. L., Yegnasubramanian, S. & Nelson, W. G. Premalignancy in prostate cancer: rethinking what we know. Cancer Prev. Res. 9, 648–656 (2016).
doi: 10.1158/1940-6207.CAPR-15-0431
Gerrin, S. J., Sowalsky, A. G., Balk, S. P. & Ye, H. Mutation profiling indicates high grade prostatic intraepithelial neoplasia as distant precursors of adjacent invasive prostatic adenocarcinoma: mutation profile of HGPIN. Prostate 76, 1227–1236 (2016).
pubmed: 27272561
pmcid: 5507580
doi: 10.1002/pros.23212
Toso, A. et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep. 9, 75–89 (2014).
pubmed: 25263564
doi: 10.1016/j.celrep.2014.08.044
Kaur, H. B. et al. Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. Mod. Pathol. 31, 1539–1552 (2018).
pubmed: 29849114
pmcid: 6168349
doi: 10.1038/s41379-018-0083-x
Kaur, H. B. et al. TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer. Hum. Pathol. 87, 95–102 (2019).
pubmed: 30851334
pmcid: 8183670
doi: 10.1016/j.humpath.2019.02.006
Patarroyo, M., Tryggvason, K. & Virtanen, I. Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin. Cancer Biol. 12, 197–207 (2002).
pubmed: 12083850
doi: 10.1016/S1044-579X(02)00023-8
Sprenger, C. C. T. et al. Senescence-induced alterations of laminin chain expression modulate tumorigenicity of prostate cancer cells. Neoplasia 10, 1350–1361 (2008).
pubmed: 19048114
pmcid: 2586686
doi: 10.1593/neo.08746
Platz, E. A. et al. A prospective study of chronic inflammation in benign prostate tissue and risk of prostate cancer: linked PCPT and SELECT cohorts. Cancer Epidemiol. Biomarkers Prev. 26, 1549–1557 (2017).
pubmed: 28754796
pmcid: 5626618
doi: 10.1158/1055-9965.EPI-17-0503
Jiang, J. et al. The role of prostatitis in prostate cancer: meta-analysis. PLoS ONE 8, e85179 (2013).
pubmed: 24391995
pmcid: 3877315
doi: 10.1371/journal.pone.0085179
Langston, M. E. et al. A systematic review and meta-analysis of associations between clinical prostatitis and prostate cancer: new estimates accounting for detection bias. Cancer Epidemiol. Biomarkers Prev. 28, 1594–1603 (2019).
pubmed: 31337640
pmcid: 6774844
doi: 10.1158/1055-9965.EPI-19-0387
de Bono, J. S. et al. Prostate carcinogenesis: inflammatory storms. Nat. Rev. Cancer 20, 455–469 (2020).
pubmed: 32546840
doi: 10.1038/s41568-020-0267-9
Shinohara, D. B. et al. A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes. Prostate 73, 1007–1015 (2013).
pubmed: 23389852
pmcid: 3991131
doi: 10.1002/pros.22648
Kirby, R. S., Lowe, D., Bultitude, M. I. & Shuttleworth, K. E. Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br. J. Urol. 54, 729–731 (1982).
pubmed: 7150931
doi: 10.1111/j.1464-410X.1982.tb13635.x
Liu, C., La Rosa, S. & Hagos, E. G. Oxidative DNA damage causes premature senescence in mouse embryonic fibroblasts deficient for Krüppel-like factor 4. Mol. Carcinog. 54, 889–899 (2015).
pubmed: 24788960
doi: 10.1002/mc.22161
Wang, B., Kohli, J. & Demaria, M. Senescent cells in cancer therapy: friends or foes? Trends Cancer 6, 838–857 (2020).
pubmed: 32482536
doi: 10.1016/j.trecan.2020.05.004
Nguyen, D. P., Li, J. & Tewari, A. K. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU Int. 113, 986–992 (2014).
pubmed: 24053309
doi: 10.1111/bju.12452
Shariat, S. F. et al. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58, 1008–1015 (2001).
pubmed: 11744478
doi: 10.1016/S0090-4295(01)01405-4
Maynard, J. P. et al. IL8 expression is associated with prostate cancer aggressiveness and androgen receptor loss in primary and metastatic prostate cancer. Mol. Cancer Res. 18, 153–165 (2020).
pubmed: 31604846
doi: 10.1158/1541-7786.MCR-19-0595
Giri, D. & Ittmann, M. Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia. Am. J. Pathol. 157, 249–255 (2000).
pubmed: 10880394
pmcid: 1850193
doi: 10.1016/S0002-9440(10)64535-X
Giri, D. & Ittmann, M. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am. J. Pathol. 159, 139–147 (2001).
pubmed: 11438462
pmcid: 1850405
doi: 10.1016/S0002-9440(10)61681-1
Castro, P., Xia, C., Gomez, L., Lamb, D. J. & Ittmann, M. Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 60, 153–159 (2004).
pubmed: 15162381
doi: 10.1002/pros.20051
Tominaga, K. & Suzuki, H. I. TGF-β signaling in cellular senescence and aging-related pathology. Int. J. Mol. Sci. 20, 5002 (2019).
pmcid: 6834140
doi: 10.3390/ijms20205002
Royuela, M. et al. Transforming growth factor beta 1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma. Growth Factors 16, 101–110 (1998).
pubmed: 9932228
doi: 10.3109/08977199809002121
Untergasser, G. et al. Profiling molecular targets of TGF-beta1 in prostate fibroblast-to-myofibroblast transdifferentiation. Mech. Ageing Dev. 126, 59–69 (2005).
pubmed: 15610763
doi: 10.1016/j.mad.2004.09.023
Walenda, G. et al. TGF-beta1 does not induce senescence of multipotent mesenchymal stromal cells and has similar effects in early and late passages. PLoS ONE 8, e77656 (2013).
pubmed: 24147049
pmcid: 3798389
doi: 10.1371/journal.pone.0077656
Wang, L. et al. Aberrant transforming growth factor-β activation recruits mesenchymal stem cells during prostatic hyperplasia. Stem Cell Transl Med. 6, 394–404 (2017).
doi: 10.5966/sctm.2015-0411
Wang, R. et al. Long noncoding RNA DNM3OS promotes prostate stromal cells transformation via the miR-29a/29b/COL3A1 and miR-361/TGFβ1 axes. Aging 11, 9442–9460 (2019).
pubmed: 31694982
pmcid: 6874426
doi: 10.18632/aging.102395
Hu, S. et al. Evidence of TGF-β1 mediated epithelial-mesenchymal transition in immortalized benign prostatic hyperplasia cells. Mol. Membr. Biol. 31, 103–110 (2014).
pubmed: 24650126
doi: 10.3109/09687688.2014.894211
Elliott, R. L. & Blobe, G. C. Role of transforming growth factor beta in human cancer. J. Clin. Oncol. 23, 2078–2093 (2005).
pubmed: 15774796
doi: 10.1200/JCO.2005.02.047
Tuxhorn, J. A. et al. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res. 8, 2912–2923 (2002).
pubmed: 12231536
Zhang, H. et al. lncRNA MIR4435-2HG promotes cancer cell migration and invasion in prostate carcinoma by upregulating TGF-β1. Oncol. Lett. 18, 4016–4021 (2019).
pubmed: 31516603
pmcid: 6732992
Paller, C. et al. TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer. Prostate 79, 31–43 (2019).
pubmed: 30155899
doi: 10.1002/pros.23708
Romero, D. et al. Dickkopf-3 regulates prostate epithelial cell acinar morphogenesis and prostate cancer cell invasion by limiting TGF-β-dependent activation of matrix metalloproteases. Carcinogenesis 37, 18–29 (2016).
pubmed: 26503968
doi: 10.1093/carcin/bgv153
Begley, L., Monteleon, C., Shah, R. B., Macdonald, J. W. & Macoska, J. A. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell 4, 291–298 (2005).
pubmed: 16300481
doi: 10.1111/j.1474-9726.2005.00173.x
Bavik, C. et al. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res. 66, 794–802 (2006).
pubmed: 16424011
doi: 10.1158/0008-5472.CAN-05-1716
Ao, M. et al. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res. 67, 4244–4253 (2007).
pubmed: 17483336
doi: 10.1158/0008-5472.CAN-06-3946
Linxweiler, J. & Junker, K. Extracellular vesicles in urological malignancies: an update. Nat. Rev. Urol. 17, 11–27 (2020).
pubmed: 31827264
doi: 10.1038/s41585-019-0261-8
Junker, K., Heinzelmann, J., Beckham, C., Ochiya, T. & Jenster, G. Extracellular vesicles and their role in urologic malignancies. Eur. Urol. 70, 323–331 (2016).
pubmed: 26924769
doi: 10.1016/j.eururo.2016.02.046
Valentino, A. et al. Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer. Clin. Transl Oncol. 19, 651–657 (2017).
pubmed: 28054319
doi: 10.1007/s12094-016-1599-5
Urbanelli, L., Buratta, S., Sagini, K., Tancini, B. & Emiliani, C. Extracellular vesicles as new players in cellular senescence. Int. J. Mol. Sci. 17, 1408 (2016).
pmcid: 5037688
doi: 10.3390/ijms17091408
Jakhar, R. & Crasta, K. Exosomes as emerging pro-tumorigenic mediators of the senescence-associated secretory phenotype. Int. J. Mol. Sci. 20, 2547 (2019).
pmcid: 6566274
doi: 10.3390/ijms20102547
Lehmann, B. D. et al. Senescence-associated exosome release from human prostate cancer cells. Cancer Res. 68, 7864–7871 (2008).
pubmed: 18829542
doi: 10.1158/0008-5472.CAN-07-6538
Alibhai, F. J. et al. Cellular senescence contributes to age-dependent changes in circulating extracellular vesicle cargo and function. Aging Cell 19, e13103 (2020).
pubmed: 31960578
pmcid: 7059145
doi: 10.1111/acel.13103
Yaman Agaoglu, F. et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 32, 583–588 (2011).
pubmed: 21274675
doi: 10.1007/s13277-011-0154-9
Foj, L. et al. Exosomal and non-exosomal urinary miRNAs in prostate cancer detection and prognosis. Prostate 77, 573–583 (2017).
pubmed: 27990656
doi: 10.1002/pros.23295
Elkhattouti, A., Hassan, M. & Gomez, C. R. Stromal fibroblast in age-related cancer: role in tumorigenesis and potential as novel therapeutic target. Front. Oncol. 5, 158 (2015).
pubmed: 26284191
pmcid: 4515566
doi: 10.3389/fonc.2015.00158
Giannoni, E. et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 70, 6945–6956 (2010).
pubmed: 20699369
doi: 10.1158/0008-5472.CAN-10-0785
Sun, D.-Y., Wu, J.-Q., He, Z.-H., He, M.-F. & Sun, H.-B. Cancer-associated fibroblast regulate proliferation and migration of prostate cancer cells through TGF-β signaling pathway. Life Sci. 235, 116791 (2019).
pubmed: 31465732
doi: 10.1016/j.lfs.2019.116791
Vickman, R. E. et al. Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment. Prostate 80, 173–185 (2020).
pubmed: 31763714
doi: 10.1002/pros.23929
Liu, Y. et al. Klotho-mediated targeting of CCL2 suppresses the induction of colorectal cancer progression by stromal cell senescent microenvironments. Mol. Oncol. 13, 2460–2475 (2019).
pubmed: 31545552
pmcid: 6822285
doi: 10.1002/1878-0261.12577
Jin, B. et al. PIM-1 modulates cellular senescence and links IL-6 signaling to heterochromatin formation. Aging Cell 13, 879–889 (2014).
pubmed: 25040935
pmcid: 4331745
doi: 10.1111/acel.12249
Deschênes-Simard, X., Kottakis, F., Meloche, S. & Ferbeyre, G. ERKs in cancer: friends or foes? Cancer Res. 74, 412–419 (2014).
pubmed: 24408923
doi: 10.1158/0008-5472.CAN-13-2381
van Deursen, J. M. Senolytic therapies for healthy longevity. Science 364, 636–637 (2019).
pubmed: 31097655
pmcid: 6816502
doi: 10.1126/science.aaw1299
Vukmanovic-Stejic, M. et al. Enhancement of cutaneous immunity during aging by blocking p38 mitogen-activated protein (MAP) kinase-induced inflammation. J. Allergy Clin. Immunol. 142, 844–856 (2018).
pubmed: 29155150
pmcid: 6127037
doi: 10.1016/j.jaci.2017.10.032
von Kobbe, C. Targeting senescent cells: approaches, opportunities, challenges. Aging 11, 12844–12861 (2019).
doi: 10.18632/aging.102557
Chen, X. & Song, E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat. Rev. Drug Discov. 18, 99–115 (2019).
pubmed: 30470818
doi: 10.1038/s41573-018-0004-1
Laberge, R.-M. et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat. Cell Biol. 17, 1049–1061 (2015).
pubmed: 26147250
pmcid: 4691706
doi: 10.1038/ncb3195
Fung, A. S., Wu, L. & Tannock, I. F. Concurrent and sequential administration of chemotherapy and the mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clin. Cancer Res. 15, 5389–5395 (2009).
pubmed: 19706800
doi: 10.1158/1078-0432.CCR-08-3007
Sprott, R. L. Biomarkers of aging and disease: introduction and definitions. Exp. Gerontol. 45, 2–4 (2010).
pubmed: 19651201
doi: 10.1016/j.exger.2009.07.008
Coppé, J.-P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, 2853–2868 (2008).
pubmed: 19053174
doi: 10.1371/journal.pbio.0060301
Brennen, W. N. & Isaacs, J. T. Mesenchymal stem cells and the embryonic reawakening theory of BPH. Nat. Rev. Urol. 15, 703–715 (2018).
pubmed: 30214054
pmcid: 7050678
doi: 10.1038/s41585-018-0087-9
Hayward, S. W., Cunha, G. R. & Dahiya, R. Normal development and carcinogenesis of the prostate. A unifying hypothesis. Ann. N. Y. Acad. Sci. 784, 50–62 (1996).
pubmed: 8651606
doi: 10.1111/j.1749-6632.1996.tb16227.x